/This press release is not for dissemination in the United States or
through US newswire services./
TSX Exchange Symbol: RVX
CALGARY, Nov. 29, 2011 /CNW/ - Resverlogix Corp. ("Resverlogix" or the
"Company") (TSX:RVX) today announced that it has closed its previously
announced private placement to subscribers in certain jurisdictions
outside Canada of 14,819,476 common shares at a price of $1.18 per
common share for gross proceeds of $17.5 million. The shares are
subject to a four month hold period.
Eastern Capital Limited subscribed for 13,200,000 common shares and NGN
BioMed Opportunity II, LP subscribed for 1,619,476 common shares.
The securities to be issued under the offering have not been, and will
not be, registered under the United States Securities Act of 1933, as
amended (the "U.S. Securities Act"), or any state securities laws, and
accordingly, may not be offered or sold within the United States except
in compliance with the registration requirements of the U.S. Securities
Act and applicable state securities requirements or pursuant to
exemptions therefrom. This press release does not constitute an offer
to sell or a solicitation of an offer to buy any of Resverlogix's
securities in the United States.
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets
with significant unmet medical needs. The NexVas™ Plaque Regression
program is the Company's primary focus which is to develop novel small
molecules that enhance ApoA-I production. These vital therapies are
focused to address the burden of atherosclerosis and other important
diseases such as Acute Coronary Syndrome, Alzheimer's disease,
Peripheral Artery Disease and Autoimmune diseases. Resverlogix Corp.'s
common shares trade on the Toronto Stock Exchange (TSX:RVX). For
further information please visit www.resverlogix.com.
Donald J. McCaffrey
President & CEO
Director of Investor Relations
SOURCE Resverlogix Corp.
For further information: